These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 8593793

  • 1. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
    Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL.
    Endocrinology; 1996 Feb; 137(2):486-94. PubMed ID: 8593793
    [Abstract] [Full Text] [Related]

  • 2. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma.
    Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3720-7. PubMed ID: 9360531
    [Abstract] [Full Text] [Related]

  • 3. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor.
    Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJ.
    Mol Endocrinol; 1994 Aug; 8(8):983-95. PubMed ID: 7997239
    [Abstract] [Full Text] [Related]

  • 4. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome.
    Roberts VJ, Barth S, el-Roeiy A, Yen SS.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1434-9. PubMed ID: 7962340
    [Abstract] [Full Text] [Related]

  • 5. Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE).
    Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PC.
    Mol Cell Endocrinol; 2001 Mar 28; 174(1-2):99-110. PubMed ID: 11306176
    [Abstract] [Full Text] [Related]

  • 6. Regulation of inhibin/activin subunit messenger ribonucleic acids (mRNAs) by activin A and expression of activin receptor mRNAs in cultured human granulosa-luteal cells.
    Erämaa M, Hildén K, Tuuri T, Ritvos O.
    Endocrinology; 1995 Oct 28; 136(10):4382-9. PubMed ID: 7664658
    [Abstract] [Full Text] [Related]

  • 7. Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells.
    Di Simone N, Hall HA, Welt C, Schneyer AL.
    Endocrinology; 1998 Mar 28; 139(3):1147-55. PubMed ID: 9492049
    [Abstract] [Full Text] [Related]

  • 8. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle.
    Roberts VJ, Barth S, el-Roeiy A, Yen SS.
    J Clin Endocrinol Metab; 1993 Nov 28; 77(5):1402-10. PubMed ID: 8077341
    [Abstract] [Full Text] [Related]

  • 9. Dynamic regulation of pituitary follistatin messenger ribonucleic acids during the rat estrous cycle.
    Halvorson LM, Weiss J, Bauer-Dantoin AC, Jameson JL.
    Endocrinology; 1994 Mar 28; 134(3):1247-53. PubMed ID: 8119165
    [Abstract] [Full Text] [Related]

  • 10. Inhibin subunit gene expression in ovarian cancer.
    Fuller PJ, Chu S, Jobling T, Mamers P, Healy DL, Burger HG.
    Gynecol Oncol; 1999 May 28; 73(2):273-9. PubMed ID: 10329046
    [Abstract] [Full Text] [Related]

  • 11. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin.
    Delbaere A, Sidis Y, Schneyer AL.
    Endocrinology; 1999 Jun 28; 140(6):2463-70. PubMed ID: 10342830
    [Abstract] [Full Text] [Related]

  • 12. Human pituitary adenomas express endogenous inhibin subunit and follistatin messenger ribonucleic acids.
    Alexander JM, Swearingen B, Tindall GT, Klibanski A.
    J Clin Endocrinol Metab; 1995 Jan 28; 80(1):147-52. PubMed ID: 7829603
    [Abstract] [Full Text] [Related]

  • 13. Pituitary follistatin and inhibin subunit messenger ribonucleic acid levels are differentially regulated by local and hormonal factors.
    Bilezikjian LM, Corrigan AZ, Blount AL, Vale WW.
    Endocrinology; 1996 Oct 28; 137(10):4277-84. PubMed ID: 8828487
    [Abstract] [Full Text] [Related]

  • 14. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
    Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC.
    Gynecol Oncol; 1998 Apr 28; 69(1):23-31. PubMed ID: 9570994
    [Abstract] [Full Text] [Related]

  • 15. Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes.
    Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T, Schneyer AL.
    Biol Reprod; 1998 Oct 28; 59(4):807-12. PubMed ID: 9746729
    [Abstract] [Full Text] [Related]

  • 16. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
    Cipriano SC, Chen L, Kumar TR, Matzuk MM.
    Endocrinology; 2000 Jul 28; 141(7):2319-27. PubMed ID: 10875231
    [Abstract] [Full Text] [Related]

  • 17. Sex difference in the action of activin-A on cell proliferation of differentiating rat gonad.
    Kaipia A, Toppari J, Huhtaniemi I, Paranko J.
    Endocrinology; 1994 May 28; 134(5):2165-70. PubMed ID: 8156918
    [Abstract] [Full Text] [Related]

  • 18. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells.
    Dalkin AC, Gilrain JT, Bradshaw D, Myers CE.
    Endocrinology; 1996 Dec 28; 137(12):5230-5. PubMed ID: 8940339
    [Abstract] [Full Text] [Related]

  • 19. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
    Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF.
    Mol Cancer Res; 2005 Jan 28; 3(1):50-61. PubMed ID: 15671249
    [Abstract] [Full Text] [Related]

  • 20. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1).
    Wang QF, Khoury RH, Smith PC, McConnell DS, Padmanahban V, Midgley AR, Schneyer AL, Crowley WF, Sluss PM.
    J Clin Endocrinol Metab; 1996 Apr 28; 81(4):1434-41. PubMed ID: 8636347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.